For research use only. Not for therapeutic Use.
Anlotinib (CAT: I000298) is an orally available small molecule that acts as an inhibitor of multiple receptor tyrosine kinases, including EGFR (epidermal growth factor receptor), VEGFR (vascular endothelial growth factor receptor), FGFR (fibroblast growth factor receptor), and PDGFR (platelet-derived growth factor receptor). It has shown promise as a targeted therapy for the treatment of non-small cell lung cancer (NSCLC). By inhibiting the activity of these kinases, Anlotinib can disrupt signaling pathways involved in tumor growth, angiogenesis, and metastasis. It has been investigated in clinical trials as a potential treatment option for various cancers, including NSCLC.
| Catalog Number | I000298 |
| CAS Number | 1058156-90-3 |
| Synonyms | AL3818; AL 3818 |
| Molecular Formula | C23H22FN3O3 |
| Purity | ≥95% |
| Solubility | DMSO: ≥ 44 mg/mL |
| Storage | -20oC Freeze |
| Related CAS | 1360460-82-7 (HCl salt) |
| InChI | InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3 |
| InChIKey | KSMZEXLVHXZPEF-UHFFFAOYSA-N |
| SMILES | CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC |
| Reference | <p> |
